Lilly To Pay Up To $755M For Autoimmune Treatments
Eli Lilly & Co. has agreed to purchase the rights to anti-inflammatory and autoimmune treatments from Incyte Corp. for up to $755 million, the companies have announced....To view the full article, register now.
Already a subscriber? Click here to view full article